The PASPORT Research Program - A global clinical research program to advance patient care

PASPORT LUNG-NETs

The PASPORT clinical trial research program will evaluate pasireotide for the treatment of a range of neuroendocrine tumors.

• At least 18 years of age with histologically confirmed, well-differentiated unresectable or metastatic neuroendocrine carcinoma of the lung or thymus
• At least one measurable lesion defined by RECIST 1.1 criteria
• Radiological confirmation of disease progression within the last 12 months
• WHO performance status of 0,1, or 2

• Poorly differentiated neuroendocrine carcinoma, non-neuroendocrine thymoma, and mixed tumors
• Prior treatment with
• Any long-acting somatostatin analogue within the last 2 months
• mTOR inhibitors
• Radioligand therapy within the last 6 months
• Chemotherapy, immunotherapy, or radiotherapy within the last 3 months
• Known intolerance or hypersensitivity to pasireotide, octreotide, or other SST analogues and everolimus, or other rapamycin analogues